ArticleBMC chemistry2025

Cutting-edge assays for mirabegron and tadalafil combo therapy for benign prostatic hyperplasia; insilico kinetics approach; multi trait sustainability assessment.

Sara I Aboras et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.